<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197779</url>
  </required_header>
  <id_info>
    <org_study_id>CV001-001</org_study_id>
    <nct_id>NCT03197779</nct_id>
  </id_info>
  <brief_title>A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS- 962212 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV&#xD;
      infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2013</start_date>
  <completion_date type="Actual">January 24, 2017</completion_date>
  <primary_completion_date type="Actual">February 2, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuation due to AE</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE of clinically significant bleeding</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE of clinically significant infusion reaction</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE of clinically significant vital signs</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcF intervals - QT interval corrected for heart rate according to Fridericia's formula</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QRS - The interval from the beginning of the Q wave and the end of the S wave</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PR - The interval from the beginning of the P wave to the beginning of the QRS complex</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour cardiac monitoring</measure>
    <time_frame>Up to 6 days</time_frame>
    <description>measured by telemetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by iohexol administration plasma clearance and the Chronic Kidney Disease-Epidemiology Collaborative Group (CKD EPI) equation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystatin-C</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by serum biomarkers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil gelatinase-associated lipocalin (NGAL)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by urine biomarkers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocyte chemoattractant protein-1 (MCP-1)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>measured by urine biomarkers</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">691</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>BMS-962212 Two Hour Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administered over 2 hours of BMS-962212</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-962212 5 Day Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administered over 5 days of BMS-962212</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-962212 and Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intravenous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-962212</intervention_name>
    <description>Intravenous Infusion administration over 2 hours or 5 days</description>
    <arm_group_label>BMS-962212 5 Day Administration</arm_group_label>
    <arm_group_label>BMS-962212 Two Hour Administration</arm_group_label>
    <arm_group_label>BMS-962212 and Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>BMS-962212 and Aspirin</arm_group_label>
    <arm_group_label>Placebo and Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo and Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination, ECG, and clinical laboratory determinations&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 to 32 kg/m2 inclusive [as calculated by BMI = weight (kg)/&#xD;
             [height (m)]2&#xD;
&#xD;
          -  This study permits the re-enrollment of a subject that has discontinued the study as a&#xD;
             pre-treatment failure (ie, subject has not been randomized / has not been treated). If&#xD;
             re-enrolled, the subject must be re-consented&#xD;
&#xD;
          -  Men, ages 18 to 45 years, inclusive; women, ages 18-45, who are not of child-bearing&#xD;
             potential&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Women of child-bearing potential&#xD;
&#xD;
          -  Current or recent (within 3 months of study drug administration) gastrointestinal&#xD;
             disease which by the judgment of the Investigator may increase a subject's risk of&#xD;
             gastrointestinal bleeding (e.g., peptic or gastric ulcer disease, severe gastritis,&#xD;
             history of gastrectomy)&#xD;
&#xD;
          -  Any major surgery within 12 weeks of study drug administration&#xD;
&#xD;
          -  History of blood transfusion, clinically significant bleeding event(s), or documented&#xD;
             genetic bleeding diathesis or thrombophilia&#xD;
&#xD;
          -  For Aspirin Containing Arm Participants Only: Known allergy to non-steroidal&#xD;
             anti-inflammatory drugs or history of intolerance or abnormal sensitivity to aspirin&#xD;
             (e.g gastrointestinal intolerance, bruising or bleeding, aspirin induced breathing&#xD;
             difficulties or nasal polyps)&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wcct Global, Llc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel International - Baltimore Epcu</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

